109 related articles for article (PubMed ID: 38744443)
1. Targeting squalene epoxidase restores anti-PD-1 efficacy in metabolic dysfunction-associated steatohepatitis-induced hepatocellular carcinoma.
Wen J; Zhang X; Wong CC; Zhang Y; Pan Y; Zhou Y; Cheung AH; Liu Y; Ji F; Kang X; Liu D; Yu J
Gut; 2024 May; ():. PubMed ID: 38744443
[TBL] [Abstract][Full Text] [Related]
2. Targeting N6-methyladenosine reader YTHDF1 with siRNA boosts antitumor immunity in NASH-HCC by inhibiting EZH2-IL-6 axis.
Wang L; Zhu L; Liang C; Huang X; Liu Z; Huo J; Zhang Y; Zhang Y; Chen L; Xu H; Li X; Xu L; Kuang M; Wong CC; Yu J
J Hepatol; 2023 Nov; 79(5):1185-1200. PubMed ID: 37459919
[TBL] [Abstract][Full Text] [Related]
3. Squalene Epoxidase Induces Nonalcoholic Steatohepatitis Via Binding to Carbonic Anhydrase III and is a Therapeutic Target.
Liu D; Wong CC; Zhou Y; Li C; Chen H; Ji F; Go MYY; Wang F; Su H; Wei H; Cai Z; Wong N; Wong VWS; Yu J
Gastroenterology; 2021 Jun; 160(7):2467-2482.e3. PubMed ID: 33647280
[TBL] [Abstract][Full Text] [Related]
4. Squalene epoxidase drives NAFLD-induced hepatocellular carcinoma and is a pharmaceutical target.
Liu D; Wong CC; Fu L; Chen H; Zhao L; Li C; Zhou Y; Zhang Y; Xu W; Yang Y; Wu B; Cheng G; Lai PB; Wong N; Sung JJY; Yu J
Sci Transl Med; 2018 Apr; 10(437):. PubMed ID: 29669855
[TBL] [Abstract][Full Text] [Related]
5. Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy.
Zhou J; Liu M; Sun H; Feng Y; Xu L; Chan AWH; Tong JH; Wong J; Chong CCN; Lai PBS; Wang HK; Tsang SW; Goodwin T; Liu R; Huang L; Chen Z; Sung JJ; Chow KL; To KF; Cheng AS
Gut; 2018 May; 67(5):931-944. PubMed ID: 28939663
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-21 receptor signaling promotes metabolic dysfunction-associated steatohepatitis-driven hepatocellular carcinoma by inducing immunosuppressive IgA
Xie Y; Huang Y; Li ZY; Jiang W; Shi NX; Lu Y; Cao G; Yin Z; Lin XJ
Mol Cancer; 2024 May; 23(1):95. PubMed ID: 38720319
[TBL] [Abstract][Full Text] [Related]
7. Squalene epoxidase promotes hepatocellular carcinoma development by activating STRAP transcription and TGF-β/SMAD signalling.
Zhang Z; Wu W; Jiao H; Chen Y; Ji X; Cao J; Yin F; Yin W
Br J Pharmacol; 2023 Jun; 180(12):1562-1581. PubMed ID: 36581319
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of 15-PGDH enhances MASH-HCC development via fatty acid-induced T-cell exhaustion.
Hu X; Yasuda T; Yasuda-Yosihara N; Yonemura A; Umemoto T; Nakachi Y; Yamashita K; Semba T; Arima K; Uchihara T; Nishimura A; Bu L; Fu L; Wei F; Zhang J; Tong Y; Wang H; Iwamoto K; Fukuda T; Nakagawa H; Taniguchi K; Miyamoto Y; Baba H; Ishimoto T
JHEP Rep; 2023 Dec; 5(12):100892. PubMed ID: 37942226
[TBL] [Abstract][Full Text] [Related]
9. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma.
Liu M; Zhou J; Liu X; Feng Y; Yang W; Wu F; Cheung OK; Sun H; Zeng X; Tang W; Mok MTS; Wong J; Yeung PC; Lai PBS; Chen Z; Jin H; Chen J; Chan SL; Chan AWH; To KF; Sung JJY; Chen M; Cheng AS
Gut; 2020 Feb; 69(2):365-379. PubMed ID: 31076403
[TBL] [Abstract][Full Text] [Related]
10. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
[TBL] [Abstract][Full Text] [Related]
11. TREM2
Tan J; Fan W; Liu T; Zhu B; Liu Y; Wang S; Wu J; Liu J; Zou F; Wei J; Liu L; Zhang X; Zhuang J; Wang Y; Lin H; Huang X; Chen S; Kuang M; Li J
J Hepatol; 2023 Jul; 79(1):126-140. PubMed ID: 36889359
[TBL] [Abstract][Full Text] [Related]
12. Squalene epoxidase drives cancer cell proliferation and promotes gut dysbiosis to accelerate colorectal carcinogenesis.
Li C; Wang Y; Liu D; Wong CC; Coker OO; Zhang X; Liu C; Zhou Y; Liu Y; Kang W; To KF; Sung JJ; Yu J
Gut; 2022 Nov; 71(11):2253-2265. PubMed ID: 35232776
[TBL] [Abstract][Full Text] [Related]
13. Squalene epoxidase (SQLE) promotes the growth and migration of the hepatocellular carcinoma cells.
Sui Z; Zhou J; Cheng Z; Lu P
Tumour Biol; 2015 Aug; 36(8):6173-9. PubMed ID: 25787749
[TBL] [Abstract][Full Text] [Related]
14. Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma.
Xiong Z; Chan SL; Zhou J; Vong JSL; Kwong TT; Zeng X; Wu H; Cao J; Tu Y; Feng Y; Yang W; Wong PP; Si-Tou WW; Liu X; Wang J; Tang W; Liang Z; Lu J; Li KM; Low JT; Chan MW; Leung HHW; Chan AWH; To KF; Yip KY; Lo YMD; Sung JJ; Cheng AS
Gut; 2023 Sep; 72(9):1758-1773. PubMed ID: 37019619
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy-induced recruitment of myeloid-derived suppressor cells abrogates efficacy of immune checkpoint blockade.
Kwong TT; Wong CH; Zhou JY; Cheng ASL; Sung JJY; Chan AWH; Chan SL
JHEP Rep; 2021 Apr; 3(2):100224. PubMed ID: 33604533
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of SQLE promotes CD8+ T cell infiltration in the tumor microenvironment.
Wu J; Hu W; Yang W; Long Y; Chen K; Li F; Ma X; Li X
Cell Signal; 2024 Feb; 114():110983. PubMed ID: 37993027
[TBL] [Abstract][Full Text] [Related]
17. Squalene epoxidase promotes colorectal cancer cell proliferation through accumulating calcitriol and activating CYP24A1-mediated MAPK signaling.
He L; Li H; Pan C; Hua Y; Peng J; Zhou Z; Zhao Y; Lin M
Cancer Commun (Lond); 2021 Aug; 41(8):726-746. PubMed ID: 34268906
[TBL] [Abstract][Full Text] [Related]
18. FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2.
Xie M; Lin Z; Ji X; Luo X; Zhang Z; Sun M; Chen X; Zhang B; Liang H; Liu D; Feng Y; Wang Y; Li Y; Liu B; Huang W; Xia L
J Hepatol; 2023 Jul; 79(1):109-125. PubMed ID: 36907560
[TBL] [Abstract][Full Text] [Related]
19. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
20. Τ cell-mediated adaptive immunity in the transition from metabolic dysfunction-associated steatohepatitis to hepatocellular carcinoma.
Papadopoulos G; Giannousi E; Avdi AP; Velliou RI; Nikolakopoulou P; Chatzigeorgiou A
Front Cell Dev Biol; 2024; 12():1343806. PubMed ID: 38774646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
